tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Soleno Therapeutics reports preliminary Q4 revenue $90M-$92M, consensus $81.67M
PremiumThe FlySoleno Therapeutics reports preliminary Q4 revenue $90M-$92M, consensus $81.67M
2d ago
Soleno Therapeutics announces publication of VYKAT XR study results in JCEM
Premium
The Fly
Soleno Therapeutics announces publication of VYKAT XR study results in JCEM
9d ago
Optimistic Outlook for Soleno Therapeutics: Potential Synergy of Vykat in Niche Market Segments
Premium
Ratings
Optimistic Outlook for Soleno Therapeutics: Potential Synergy of Vykat in Niche Market Segments
1M ago
Soleno board authorizes $100M Accelerated Share Repurchase Agreement
PremiumThe FlySoleno board authorizes $100M Accelerated Share Repurchase Agreement
2M ago
Soleno Therapeutics: Strong Q3 Performance and Market Potential Justify Buy Rating
Premium
Ratings
Soleno Therapeutics: Strong Q3 Performance and Market Potential Justify Buy Rating
2M ago
Soleno Therapeutics’ Financial Challenges: Navigating Risks in VYKAT XR Commercialization
Premium
Company Announcements
Soleno Therapeutics’ Financial Challenges: Navigating Risks in VYKAT XR Commercialization
2M ago
Soleno Therapeutics price target lowered to $106 from $123 at Wells Fargo
PremiumThe FlySoleno Therapeutics price target lowered to $106 from $123 at Wells Fargo
2M ago
Soleno Therapeutics Achieves Profitability with VYKAT XR Launch
Premium
Company Announcements
Soleno Therapeutics Achieves Profitability with VYKAT XR Launch
2M ago
Soleno Therapeutics: Strong Sales Growth and Profitability Drive Buy Rating
Premium
Ratings
Soleno Therapeutics: Strong Sales Growth and Profitability Drive Buy Rating
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100